Guidelines and Recommendations
Showing: 41 -
60
of 481 results
10
20
50
results per page
-
Corporate Author:
Bureau of HIV/AIDS, STD and TB, Population and Public Health Branch, Health Canada, Ottawa, Ontario, Canada.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2003; 52(RR-2):1-13.
Description:
These guidelines replace CDC's 1995 guidelines, U.S. Public Health Service Recommendations for Human Immunodeficiency Virus Counseling and Voluntary Testing for Pregnant Women, and are for public- and private-sector service providers who provide heal...
-
Corporate Author:
Division of Viral Hepatitis, National Center for Infectious Diseases;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2003; 52(RR-3):1-13, 15; quiz CE1-4.
Description:
The following statement updates all previous recommendations on protection against hepatitis B virus infection, including use of hepatitis B vaccine and hepatitis B immune globulin for prophylaxis against hepatitis B virus infection (MMWR 1985;34:313...
-
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2003; 52(RR-11):1-77.
Description:
Until 2001, the only test used to diagnose latent tuberculosis infection (LTBI) was the tuberculin skin test (TST). However, in 2001, a new test (QuantiFERON-TB or QFT; manufactured by Cellestis Limited, Carnegie, Victoria, Australia) that measures t...
-
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2003; 52(RR-12):1-24.
Description:
Monitoring human immunodeficiency virus type 1 (HIV-1) ribonucleic acid levels (also known as HIV viral load) has become the standard of care for monitoring response to therapy in HIV-infected patients. In 1999, CDC published updated surveillance cas...
-
Source:
MMWR. Morbidity and mortality weekly report.
2003; 52(31):735-9.
Description:
A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficienc...
-
Corporate Author:
Division of TB Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), USA.;
Source:
MMWR. Morbidity and mortality weekly report.
2004; 53(30):683-6.
-
Corporate Author:
Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC, Atlanta, Georgia 30333, USA.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-2):1-20.
Description:
The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). In 1996, the Depa...
-
Corporate Author:
Division of TB Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), USA.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-6):1-12.
-
Corporate Author:
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, CDC, 1600 Clifton Rd., NE, MS E-68, Atlanta, Georgia 30333, USA.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-9):1-17.
Description:
These recommendations update the February 4,2002, guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides health...
-
Corporate Author:
National Center for HIV, STD, and TB Prevention, CDC, USA.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-12):1-81.
Description:
Since the mid-1990s, public health laboratories have improved tuberculosis (TB) test performance, which has contributed to the resumption of the decline in TB incidence in the United States. However, to eliminate TB in the United States, further impr...
-
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-15):1-47.
Description:
During 1993-2003, incidence of tuberculosis (TB) in the United States decreased 44% and is now occurring at a historic low level (14,874 cases in 2003). The Advisory Council for the Elimination of Tuberculosis has called for a renewed commitment to e...
-
Corporate Author:
Division of Viral Hepatitis, National Center for Infectious Diseases;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2005; 54(RR-16):1-31.
Description:
This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous r...
-
Corporate Author:
Division of Viral Hepatitis, National Center for Infectious Diseases;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2006; 55(RR-7):1-23.
-
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2006; 55(RR-9):1-44.
Description:
On May 2, 2005, a new in vitro test, QuantiFERON-TB Gold (QFT-G, Cellestis Limited, Carnegie, Victoria, Australia), received final approval from the U.S. Food and Drug Administration as an aid for diagnosing Mycobacterium tuberculosis infection. This...
-
Corporate Author:
Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), Atlanta, GA 30333, USA.;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2006; 55(RR-14):1-17; quiz CE1-4.
Description:
These guidelines were developed by CDC for laboratorians who perform immunophenotyping for detection and enumeration of CD4+ T-cells and other lymphocyte subsets in persons infected with human immunodeficiency virus (HIV). The guidelines describe sin...
-
Corporate Author:
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed);
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2006; 55(RR-16):1-33; quiz CE1-4.
Description:
Routine vaccination of children is the most effective way to reduce hepatitis A incidence nationwide over time. Since licensure of hepatitis A vaccine in 1995, this strategy has been implemented incrementally, starting with the recommendation of the ...
-
Corporate Author:
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention;
Source:
MMWR. Morbidity and mortality weekly report.
2007; 56(41):1080-4.
Description:
This report updates and consolidates all previous U.S. Public Health Service recommendations for the management of health-care personnel (HCP) who have occupational exposure to blood and other body fluids that might contain hepatitis B virus (HBV), h...
-
Corporate Author:
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention;
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2008; 57(RR-8):1-20.
Description:
Routine vaccination of children is an effective way to reduce hepatitis A incidence in the United States. Since licensure of hepatitis A vaccine during 1995-1996, the hepatitis A childhood immunization strategy has been implemented incrementally, sta...
-
Source:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control.
2008; 57(RR-9):1-83; quiz CE1-4.
Description:
These guidelines for the treatment of patients who have sexually transmitted diseases (STDs) were developed by CDC staff members after consultation with a group of invited experts who met in Atlanta on February 10-12, 1997. The information in this re...
-
Source:
MMWR. Morbidity and mortality weekly report.
2009; 58(1):7-10.
Description:
CDC has reported previously surveillance data of severe liver injury in patients treated for latent tuberculosis infection (LTBI) with a daily and twice-weekly 2-month regimen of rifampin with pyrazinamide (RZ). On the basis of these initial reports,...
[PDF - 397.78 KB]
